Key result
Shockwave therapy plus hiPSC-MSC exosomes boosts limb perfusion ~40% over exosomes alone.
Why the study?
Regenerative options for peripheral arterial disease are limited, and although mesenchymal stem cell exosomes and extracorporeal shockwave therapy individually promote angiogenesis, whether combining them augments vascular recovery was unknown.
Does combining extracorporeal shockwave therapy with hiPSC-MSC exosomes improve blood perfusion recovery in a murine hindlimb ischaemia model?
RCT (n=24)
Randomized into four groups (n=6/group)
Does combining extracorporeal shockwave therapy with hiPSC-MSC exosomes improve blood perfusion recovery in a murine hindlimb ischaemia model?
Answers are grounded in this paper and cite their sources.
Combining extracorporeal shockwave therapy with hiPSC-MSC-derived exosomes provides an additive benefit in improving limb perfusion, reducing fibrosis, and increasing neovascularisation in a preclinical model of hindlimb ischaemia.
Background Peripheral arterial disease (PAD) is characterised by limb ischaemia and impaired perfusion, with limited regenerative options. Exosomes from mesenchymal stem cells have pro-angiogenic potential, while extracorporeal shockwave therapy promotes neovascularisation. Whether combining biophysical stimulation with exosome-based therapy augments vascular recovery is unknown. Purpose To evaluate the effects of shockwave therapy and human iPSC-derived mesenchymal stem cell (hiPSC-MSC) exosomes, alone and in combination, on perfusion recovery in a murine hindlimb ischaemia model. Methods Hindlimb ischaemia was induced by femoral artery ligation in ICR mice, which were randomised into four groups (n=6/group): control, hiPSC-MSC exosomes, shockwave, and combination therapy. Exosomes (35 μg in saline) were injected intramuscularly immediately after ischaemia induction. Shockwave therapy (0.20 mJ/mm², 5 Hz) was applied in four sessions: immediately post-operatively and at weeks 1, 2, and 3. Blood perfusion was assessed by laser Doppler imaging immediately post-operatively and at 1, 2, 3, and 4 weeks. At 4 weeks, hindlimb tissues were collected for Masson’s trichrome and immunohistochemical staining. One-way ANOVA with post hoc testing was used for statistical analysis. Results At week 4, both exosome and shockwave monotherapies significantly improved perfusion versus control (314.74 perfusion units [PU] vs 177.03 PU and 343.48 PU vs 177.03 PU, respectively; both p<0.05). Combination therapy achieved the highest perfusion (441.36 PU), significantly greater than exosomes alone (441.36 PU vs 314.74 PU; p<0.05). Histology demonstrated reduced fibrosis and increased neovascularisation in the combination group compared with all other groups. Conclusion Shockwave therapy improves perfusion recovery in murine hindlimb ischaemia and provides an additive benefit when combined with hiPSC-MSC–derived exosomes. This combinatorial approach integrating biophysical stimulation with exosome-based therapy may represent a promising regenerative strategy for ischaemic vascular disease.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2026) conducted an RCT in Murine hindlimb ischaemia (Peripheral arterial disease model) (n=24). Shockwave therapy combined with hiPSC-MSC exosomes vs. Control, hiPSC-MSC exosomes alone, or shockwave therapy alone was evaluated on Blood perfusion (in perfusion units [PU]) assessed by laser Doppler imaging at week 4 (p=<0.05). Combining shockwave therapy with hiPSC-MSC exosomes achieved greater week-4 limb perfusion than exosomes alone or control.
Synapse has enriched 10 related papers. Consider them for comparative context: